Company / Shareholders' Equity
CRISPR Therapeutics AG Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.9B
FY2025
5-year range
$1.9B / $2.4B
FY2021-FY2025
Trend
-0.5%
vs FY2024
Sector context
#29 of 215
Health Care
What the data says
CRISPR Therapeutics AG's shareholders' equity of $1.9B is higher than 87% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from $188M in FY2017 to $2.4B in FY2021.
Based on SEC 10-K filings.
$1.9B in FY2025 with a 5-year CAGR of +2.9%. Top quartile in the Health Care sector.
Improved from $1.9B to $1.9B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +0.8%
- 5-Year CAGR
- +2.9%
- 10-Year CAGR
- -
Sector benchmark
-24.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.9%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 0.5% year-over-year.
- Ranks #29 out of 215 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.9B | -0.5% |
| FY2024 | $1.9B | +2.6% |
| FY2023 | $1.9B | +0.4% |
| FY2022 | $1.9B | -21.8% |
| FY2021 | $2.4B | +44.2% |
| FY2020 | $1.7B | +77.2% |
| FY2019 | $939.4M | +139.5% |
| FY2018 | $392.2M | +108.8% |
| FY2017 | $187.8M | -19.3% |
| FY2016 | $232.8M | +899.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026